NetworkNewsBreaks

WednesdayJul 19, 2023 1:57 pm

NetworkNewsBreaks – CISO Global Inc. (NASDAQ: CISO) Announces Strategic Acquisition of SB Cyber Technologies LLC

CISO Global Inc. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, today announced that it has acquired SB Cyber Technologies, a cybersecurity company that specializes in identifying, enhancing and applying emerging government and military grade capabilities to critical commercial technical security challenges. Under the agreement, SC Cyber has become a wholly owned subsidiary of CISO Global. Based in Chesapeake, Virginia, and founded by former members of the U.S. intelligence and special operations communities, SB Cyber developed CHECKLIGHT(R), a powerful and proactive endpoint detection and response (“EDR”) technology that detects potential threats to endpoints, such as laptops…

Continue Reading

WednesdayJul 19, 2023 1:52 pm

NetworkNewsBreaks – Data443 Risk Mitigation Inc. (ATDS) Positioned to Continue Growing Relationships in Fintech on Strength of Security Offerings

Data443 Risk Mitigation (OTC: ATDS), a data security and privacy software company, recently added antivirus and ransomware protection to its Enhanced File Transfer/Managed File Transfer (“EFT/MFT”) solution. “The company recently announced the enhancement of its Data Placement Manager (‘DPM’), an EFT/MFT solution, with antivirus and ransomware protection additions powered by the company’s Ransomware Recovery Manager (‘RRM’), which was named ‘Best for Inexpensive Protection’ and ‘Best for Kiosks’ by PC Mag. In a bid to enhance its data security and protection capabilities and cyber threat intelligence (‘CTI’) services, the company has recently closed a definitive agreement to acquire select assets from…

Continue Reading

WednesdayJul 19, 2023 1:44 pm

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its entry into definitive agreements with health care-focused institutional investors. The agreements are for the sale and issuance of 7,425,744 shares of the company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $0.885 per share, exercisable at the date of issuance…

Continue Reading

WednesdayJul 19, 2023 12:33 pm

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Continues Sales Momentum with Announcement of Three New Orders

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has received three new sales, for a total of eight new units. The sales, which came from a military base, a mall and a university, come on the heels of a consistent stream of orders the company has received. According to the announcement, the Nellis Air Force Base is expanding the use of K1 Retrofit Kits through a Knightscope reseller; the base has 20 competitor products that have been retrofitted with Knightscope’s modern technologies. The result is extremely cost-effective systems that utilize cellular…

Continue Reading

WednesdayJul 19, 2023 12:00 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it was granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office (“USPTO”). According to the update, U.S. patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. The company’s superior DehydraTECH processing and sublingual compositions have now been recognized through exceptional scientific study results as well as…

Continue Reading

TuesdayJul 18, 2023 2:54 pm

NetworkNewsBreaks – Bollinger Motors, a Majority-Owned EV Truck Company of Mullen Automotive Inc. (NASDAQ: MULN), Kicks off ‘Design Validation’ Pilot Builds

Bollinger Motors, which in September of 2022 became a majority-owned EV truck company of Mullen Automotive (NASDAQ: MULN), today announced the start of its “design validation” pilot builds of the B4 all-electric Class 4 chassis cabs for testing and demonstration. According to the announcement, manufacturing of the pilot vehicles has kicked off in partnership with Roush Industries Inc. at its facility in Livonia, Michigan. The first five completed chassis cabs are expected to roll out this summer, with another 15+ vehicles by the end of the third quarter of 2023. “Bollinger Motors has over eight years of experience in developing,…

Continue Reading

TuesdayJul 18, 2023 2:00 pm

NetworkNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Completes Game-Changing Integration with Samsara

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility and simplicity, recently announced its new integration with Samsara, a pioneer of the Connected Operations(TM) Cloud. “Samsara’s Connected Operations Cloud has helped differentiate the company in its segment by making it easy for organizations to access, analyze and act upon real-time data from tracks, trailers, warehouses, and equipment. In turn, users have enjoyed improved safety, efficiency, and sustainability, allowing for better and even more profitable operations. With the integration, Fr8App customers can now view…

Continue Reading

TuesdayJul 18, 2023 1:38 pm

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has signed an exclusive license agreement with the University of Pittsburgh. The agreement grants Genprex worldwide, exclusive rights to a patent application and related technology for a gene therapy targeting both type 1 and type 2 diabetes. The therapy utilizes Pdx1 (“Pdx1”) and MafA (“MafA”) genes controlled by an MafB (“MafB”) promoter and administered through an adeno-associated virus (“AAV”) vector directly into the pancreatic duct. Preclinical data from nonhuman primate models of type 1 diabetes show promising results, with significant decreases…

Continue Reading

TuesdayJul 18, 2023 1:20 pm

NetworkNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Presenting 6 Posters on Its Lead Therapeutic Candidate at AAIC 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced that it is presenting six in-person posters highlighting data from its phase 1 clinical trials investigating the company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”). The event is taking place July 16-20, 2023, in Amsterdam, Netherlands. “We are honored to have six posters accepted for presentation at AAIC 2023, a prestigious meeting of leading Alzheimer’s disease experts and pharmaceutical innovators,” said Ram Mukunda, CEO of IGC. “The data being presented at AAIC from our phase 1 clinical trial of IGC-AD1 demonstrates the positive impact of…

Continue Reading

TuesdayJul 18, 2023 1:03 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that an arbitration panel has found that Syneos Health (NASDAQ: SYNH) failed to use commercially reasonable efforts in conducting its trial for FSD 201. According to the announcement, Syneos Health filed an arbitration proceeding against FSD Pharma in 2022. Syneos claimed that FSD Pharma owed Syneos Health $3,915,388.69 in damages as well as interest on that amount in relation to a failed phase 2 FDA trial…

Continue Reading